Vantictumab

Drug Profile

Vantictumab

Alternative Names: Anti-frizzled receptor monoclonal antibody - OncoMed; Anti-Fzd receptor monoclonal antibody - OncoMed; anti-Fzd7; Anti-Fzd7 receptor monoclonal antibody - OncoMed; OMP-18R5

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
  • Developer OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Frizzled-receptor-antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 08 Mar 2017 OncoMed Pharmaceuticals intends to submit data package for Vantictumab to Bayer for opt-in consideration in the first half of 2017
  • 10 Oct 2016 Efficacy and adverse events data from a phase Ib trial in Pancreatic cancer presented at the European Society of Medical Oncology (ESMO-2016) Congress
  • 05 Jun 2016 Interim efficacy and adverse events data from a phase Ib trial in Breast cancer presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top